Status:
COMPLETED
Ultrasound-guided Injection of Glucocorticoid Into Infrapatellar Fat Pad in Patients With Knee Osteoarthritis
Lead Sponsor:
Zhujiang Hospital
Conditions:
Osteoarthritis, Knee
Eligibility:
All Genders
45+ years
Phase:
PHASE4
Brief Summary
This aims of this study is to investigate the efficacy and safety of the glucocorticoid injection into the infrapatellar fat pad among knee osteoarthritis patients with an inflammatory phenotype.
Eligibility Criteria
Inclusion
- Diagnosed with symptomatic knee osteoarthritis (OA) according to American College of Rheumatology criteria;
- Age \> 45 years;
- Have knee pain for more than six months and the knee pain over the past week assessed by VAS (100 mm) ≥ 40 mm;
- Ultrasonography showed obvious synovitis with effusion in the knee joint;
- Both MRI-assessed Hoffa-synovitis score (MOAKS method) and effusion-synovitis score (modified WORMS method) ≥ 1, and their total score ≥ 3;
- Being able to listen, speak, read and understand Chinese, capable of understanding the study requirements and cooperating with the researchers during the study, and providing written informed consent.
Exclusion
- Allergy to glucocorticoids;
- Knee injection of glucocorticoid or hyaluronic acid within the past six months;
- Severe trauma or arthroscopy in the knee within the past six months;
- Planned hip or knee surgery (including arthroscopy, arthroplasty, and other open joint surgeries) in the next six months;
- Contraindication to having magnetic resonance imaging (MRI) (e.g., implanted pacemaker, artificial metal valve or cornea, aneurysm clipping surgery, arterial dissection, metal foreign bodies in the eyeball, claustrophobia);
- Presence of other arthritis, such as rheumatoid arthritis and psoriatic arthritis;
- Other physical condition that is more painful than their knee OA;
- Malignant tumors or other life-threatening diseases;
- Infection, diabetes, coagulopathy, osteonecrosis, or gastric/duodenal ulcer within the past 12 months;
- Current use of oral corticosteroids, nonsteroidal anti-inflammatory drugs, or immunosuppressive medication;
- Pregnancy or lactating female;
- Use any investigational drugs or devices in the recent 30 days.
Key Trial Info
Start Date :
April 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 26 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05291650
Start Date
April 25 2022
End Date
December 26 2023
Last Update
December 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhujiang Hospital
Guangzhou, China, 510280